MBC BioLabs and AbbVie 2020 Golden Ticket

The AbbVie Golden Ticket will be awarded to an early stage company developing novel, transformational therapies for autoimmune, oncology, or neurodegenerative disease.

The winner will receive:

  • Priority admission or renewal for one year's use of a lab bench and core facilities at MBC BioLabs' San Francisco or San Carlos site;
  • Opportunities to engage with AbbVie scientific and business leaders.

To apply, send your non-confidential company presentation to by February 10. Semi-finalists will be invited for an in-person presentation at MBC BioLabs in April.

MBC BioLabs New Facility Tours
Join us for February hard-hat tours of our new San Carlos location on:
  • Friday 2.14.20 2 pm @ 930 Brittan Ave, San Carlos
  • Wednesday 2.19.20 2 pm @ 930 Brittan Ave, San Carlos
  • Friday 2.28.20 2 pm @ 930 Brittan Ave, San Carlos
Please e-mail to save a spot in one of our regularly scheduled tours or to have us set up just the right time that works for you.
CellFE Raises $3.6M in Seed Roud

CellFe, an innovative startup developing a microfluidics based device to deliver gene-editing molecules and a MBC BioLas San Carlos resident company, announced it has raised $3.6 million in an initial Series Seed. Read Full Article.

Lunch Seminar with AbbVie:
Strategies to New Therapies for Auto-immune and Chronic Inflammatory Diseases

February 25, 2020 from 12:00 to 1:30 PM
MBC BioLabs San Francisco
About the Speaker:

Lisa M. Olson, Ph.D.
AbbVie Vice President, Immunology Research
Site Head, AbbVie Bioresearch Center Inc.

Dr. Lisa Olson is responsible for the oversight and strategic development of AbbVie's Immunology research program, and is Site Head for the AbbVie Bioresearch Center in Worcester, MA.
Following a post-doctoral fellowship at the University of Chicago, Chicago, IL, Dr. Olson joined the faculty of the OB/GYN Department, Washington University Medical School, St. Louis, MO.  In 1998, Olson left Washington University to lead the Women's Health Program within the Nutrition Sector of Monsanto Corp., St. Louis, MO.  Two years later, she joined the Arthritis and Inflammation Department at Pharmacia Corp, St. Louis, MO which subsequently evolved into the Inflammation Department of Pfizer Corp, St. Louis, MO.  Dr. Olson joined AbbVie (formerly Abbott) in 2005 as Director, Pharmacology and has had roles of increasing responsibility ever since.  In 2008, she was promoted to Senior Director, Pharmacology and Discovery Safety, Metabolism and Pharmokinetics and in 2010 became Divisional Vice President, Immunology Research.  Dr. Olson became Site Head of the AbbVie Bioresearch Center in 2012 and the Cambridge Research Center in 2018.
Dr. Olson received her Ph.D. degree at the University of Illinois, Urbana, IL in 1986.  She currently serves on the Board of Directors for the Massachusetts Biotechnology Council and is a Trustee for the Massachusetts Biomedical Initiatives.   

Labii ELN & LIMS Lunch Seminar
February 12, 2020 from 12:00 to 1:00 PM
RSVP San Francisco
February 19, 2020 from 12:00 to 1:00 PM
RSVP San Carlos
Please join us for an invitation-only lunch to learn about how to manage your research data with Labii ELN & LIMS presented by Yonggan Wu, Relationship Manager at Labii Inc. The seminar will cover the basics of Labii ELN & LIMS and follows with a live demonstration.

About Labii:

Labii facilitates research and development by providing user-friendly, customizable Electronic Lab Notebook (ELN) and Laboratory Information Management System (LIMS) to document, manage, and interpret data. Labii ELN & LIMS can be configured for any type of data, and the functions can easily be enhanced and expanded by stand-alone applications. We address the unique needs of each of our customers and are the trusted provider of hundreds of biotech companies and academic labs.


Celevity (Cellular Longevity, Inc.) is developing drugs to correct the genetic mistakes caused by inbreeding in dogs. 

Dren bio is a biotechnology company developing engineered protein and cellular therapies for depletion of pathological cells and other disease causing agents. Dren is developing products to treat certain leukemias, lymphomas and autoimmune disorders, with the potential to expand into other disease areas.